https://endpts.com/roche-cuts-phii-eye-disease-program-one-day-after-another-biotech-flopped-in-same-indication/
0
0
10/19/22 at 11:41am
Organization
Endpoints News
Author
Paul Schloesser
Right after NGM failed to meet the primary endpoint in a Phase II eye disease trial, one of the Big Pharmas decided to remove a mid-stage candidate from its pipeline. The update was quiet, announced in Roche's Q3 earnings presentation, where the Swiss pharma …
Create an account
or login to join the discussion